Interview with Paul A. Bunn, Jr., MD

Tom Dilling
University of Pennsylvania Cancer Center
Last Modified: May 20, 1996

Share article


Dr. Bunn: There are six new drugs which have been approved or are about to be approved for treating lung cancer and they're probably all six of them better than drugs which we've had in the past, and I think they will improve survival for patients with lung cancer.

I guess the second point is that the patients who have "earlier-stage" [lung cancer], if you give them chemotherapy with radiation or with surgery or all three together, it is providing better survival than what we had in the past with just surgery alone.

And the last thing you can tell your people is: Don't smoke!

OncoLink: Just to reiterate again for all our listeners and readers out there who were not at this talk....

Dr. Bunn: They're not here? I thought they were all here!

  • laugh
  • OncoLink: Yes, well....

    What were those six new drugs which you see as on the forefront?

    Dr. Bunn: There's two taxanes, paclitaxel and docetaxel, which some people call taxol and taxotere; there's two topoisomerase I inhibitors, irinotecan and topotecan; and then there's navelbine and gemcitabine (Gemzar®).



  • I Wish You Knew

    How cancer patients have changed my life

    View More



    Blogs and Web Chats

    OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




    OncoLink OncoPilot

    Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

    Learn More



    OncoLink Cancer Treatment and Resources